MMWR Vol. 64 / Early Release

MMWR Early Release Vol. 64, Early Release November 24, 2015

In this report

PDF

Vital Signs: Estimated Percentages and Numbers of Adults with Indications for Preexposure Prophylaxis to Prevent HIV Acquisition — United States, 2015 Dawn K. Smith, MD; Michelle Van Handel, MPH; Richard J. Wolitski, PhD; et al. MMWR Morb Mortal Wkly Rep 2015;64(Early Release):1-6 Preexposure prophylaxis (PrEP) with daily oral antiretroviral medication is a new, highly effective intervention that could reduce the number of new HIV infections. CDC analyzed nationally representative data to estimate the percentages and numbers of persons in the United States, by transmission risk group, with indications for PrEP consistent with the 2014 U.S. Public Health Service’s PrEP clinical practice guideline. This report summarizes that analysis.

PDF

Vital Signs: Increased Medicaid Prescriptions for Preexposure Prophylaxis Against HIV infection — New York, 2012–2015 Franklin N. Laufer, PhD; Daniel A. O’Connell, MA, MLS; Ira Feldman, MPS; et al. MMWR Morb Mortal Wkly Rep 2015;64(Early Release):1-6 Truvada is a key component of New York’s plan to end HIV/AIDS as an epidemic in the state by 2020. Prescription data from the New York state Medicaid program from July 2012 through June 2015 were analyzed with an algorithm using medication and diagnoses codes to identify continuous use of Truvada for > 30 days, after excluding use for postexposure prophylaxis or treatment of HIV or chronic hepatitis B infection.

Vital Signs: Increased Medicaid Prescriptions for Preexposure Prophylaxis Against HIV infection — New York, 2012–2015